DIM
REGN icon

DLK Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

DLK Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-765
Closed -$591K – 121
2026
Q1 		$591K Hold
765
– – 0.23% 47
2025
Q4 		$590K Hold
765
– – 0.22% 47
2025
Q3 		$430K Hold
765
– – 0.16% 54
2025
Q2 		$402K Buy
+765
New +$427K 0.15% 57

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

DLK Investment Management's REGN Position: Q2 2026 in Review

DLK Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 765 shares — an estimated $591K sold.

DLK Investment Management first reported a position in REGN in Q2 2025 and held it in 4 quarters. The position peaked at $591K in Q1 2026. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • DLK Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DLK Investment Management sold 765 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $591K.
  • DLK Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • DLK Investment Management's Regeneron Pharmaceuticals position peaked at $591K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on DLK Investment Management's 13F filing for Q2 2026, filed 14 Jul 2026.